We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Minerva (NERV) Provides Phase III Development Strategy for MIN-101
Read MoreHide Full Article
Minerva Neurosciences, Inc. (NERV - Free Report) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101. MIN-101 is being evaluated for the treatment of negative symptoms of schizophrenia. The company made this announcement following an "end-of-Phase II” meeting with the FDA.
Minerva’s share price has declined 29.3% year to date, while the Zacks classified Medical-Drugs industry witnessed a gain of 7.2%.
The company plans to initiate the phase III study of MIN-101 in the second half of 2017. The data from the phase IIb study with MIN-101 have led to the design of the phase III study.
The phase III trial design will be a 12-week, placebo-controlled, monotherapy study testing two doses of MIN-101 in patients with negative symptoms and a diagnosis of schizophrenia. The patients will be required to have stable negative and positive symptoms over several months prior to enrollment, with a specified minimum threshold baseline score on the Positive and Negative Syndrome Scale (PANSS) negative sub-scale in order to be eligible for the study.
The study will be followed by an optional 36-week extension phase in which all patients will receive MIN-101. The study is expected to enroll 500 patients at about 60 clinical sites across the U.S. and Europe.
The primary phase III trial endpoint of improvement in negative symptoms at 12 weeks will be measured by the PANSS negative sub-scale score using the Marder factor. Secondary efficacy endpoints will include the Clinical Global Impression of Severity (CGI-S) scale and Personal and Social Performance (PSP) total score.
The phase III study is similar to the phase IIb study which met its primary endpoint. The phase II b study showed improvement in schizophrenic patients with negative symptoms treated with MIN-101 compared to placebo. The phase IIb study was completed in 2016.
The company plans to conduct additional trials to expand the profile of MIN-101. These may potentially include a study comparing the rate of psychosis relapses in patients treated with MIN-101, standard of care with antipsychotics or placebo.
Based on positive data from the phase III study, along with the positive data from the phase IIb study, Minerva plans to file a new drug application with the FDA.
Minerva currently carries a Zacks Rank #3 (Hold). Some better ranked stocks in the health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Aeglea BioTherapeutics . While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Aeglea carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the last 60 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 for 2017 over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Aeglea’s loss per share estimates narrowed from $3.64 to $2.48 for 2017 over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 20.75%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Minerva (NERV) Provides Phase III Development Strategy for MIN-101
Minerva Neurosciences, Inc. (NERV - Free Report) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101. MIN-101 is being evaluated for the treatment of negative symptoms of schizophrenia. The company made this announcement following an "end-of-Phase II” meeting with the FDA.
Minerva’s share price has declined 29.3% year to date, while the Zacks classified Medical-Drugs industry witnessed a gain of 7.2%.
The company plans to initiate the phase III study of MIN-101 in the second half of 2017. The data from the phase IIb study with MIN-101 have led to the design of the phase III study.
The phase III trial design will be a 12-week, placebo-controlled, monotherapy study testing two doses of MIN-101 in patients with negative symptoms and a diagnosis of schizophrenia. The patients will be required to have stable negative and positive symptoms over several months prior to enrollment, with a specified minimum threshold baseline score on the Positive and Negative Syndrome Scale (PANSS) negative sub-scale in order to be eligible for the study.
The study will be followed by an optional 36-week extension phase in which all patients will receive MIN-101. The study is expected to enroll 500 patients at about 60 clinical sites across the U.S. and Europe.
The primary phase III trial endpoint of improvement in negative symptoms at 12 weeks will be measured by the PANSS negative sub-scale score using the Marder factor. Secondary efficacy endpoints will include the Clinical Global Impression of Severity (CGI-S) scale and Personal and Social Performance (PSP) total score.
The phase III study is similar to the phase IIb study which met its primary endpoint. The phase II b study showed improvement in schizophrenic patients with negative symptoms treated with MIN-101 compared to placebo. The phase IIb study was completed in 2016.
The company plans to conduct additional trials to expand the profile of MIN-101. These may potentially include a study comparing the rate of psychosis relapses in patients treated with MIN-101, standard of care with antipsychotics or placebo.
Based on positive data from the phase III study, along with the positive data from the phase IIb study, Minerva plans to file a new drug application with the FDA.
Minerva Neurosciences, Inc Price
Minerva Neurosciences, Inc Price | Minerva Neurosciences, Inc Quote
Zacks Rank & Stocks to Consider
Minerva currently carries a Zacks Rank #3 (Hold). Some better ranked stocks in the health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Aeglea BioTherapeutics . While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Aeglea carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the last 60 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 for 2017 over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Aeglea’s loss per share estimates narrowed from $3.64 to $2.48 for 2017 over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 20.75%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>